Navigation Links
OncoTAb Blood Test Enables Earlier Detection of Breast Cancer in Women with Dense Breast Tissue
Date:1/26/2016

OncoTAb, Inc., a University of North Carolina at Charlotte (UNCC) spin-out company, released the findings from a clinical study testing its Agkura™ Personalized Score, a non-invasive blood test for the early detection of breast cancer in women with dense breast tissue. Data from more than 750 patient samples showed that the technology, a patented, monoclonal antibody known as TAB-004, accurately detects a specific biomarker present in more than 90 percent of breast cancer patients and is specific to all major breast cancer subtypes, including triple negative breast cancer (TNBC). The blood test will be made available online in Q1, 2016, on the order of a physician or other licensed health care provider, as a supplement to mammography.

“Half of all women have a higher risk for a missed diagnosis on a mammogram due to high breast density. Attempting to identify breast cancer on these mammograms is comparable to looking for a specific snowflake in a snowstorm,” said OncoTAb CEO Rahul Puri. “For the 10 percent of women with extremely dense breast tissue, the risk of a missed diagnosis is four to six times higher. Using our antibody, we are able to personalize the blood serum marker levels and build an early detection strategy for women with dense breast tissue.”

A study published by The New England Journal of Medicine found that 50 percent of all cancers found within 12 months of a negative test were attributed to high breast density. Chad Livasy, MD, a breast pathologist for the Carolinas HealthCare System, reviewed 440 test samples and noted TAB-004’s high level of accuracy.

“The staining is so specific with TAB-004, for most cases of mammary carcinoma immunoreactivity in the tumor (the interaction process between the antibody and breast cancer) can be appreciated even without the microscope,” said Livasy. “You can just hold the slide up to visualize the strong staining. In contrast, benign lesions show absence of staining. Given this specificity, OncoTAb’s blood test may be a useful supplemental test with mammography for women with dense breast tissue.”

The TAB-004 antibody has also shown promise beyond early diagnosis. According to OncoTAb Co-founder and Chief Science Officer Pinku Mukherjee, future applications could change the way breast cancer is treated.

“The data clearly demonstrates that this antibody can be used to target tumors in vivo with promising imaging and therapeutic applications,” said Mukherjee. “These possibilities include the development of Chimeric Antigen Receptor (CAR) engineered T-cells for treating TNBC—one of the most difficult cancers to treat.”

This press release is neither an offer to sell nor the solicitation of an offer to buy shares or any other security in any jurisdiction.

About OncoTAb, Inc.

OncoTAb (http://www.oncotab.com) is a University of North Carolina at Charlotte (UNCC) spin-out company that has a patent-protected technology. Its applications span the life cycle of cancer patients, from detecting and locating cancer to treatment and monitoring for recurrence. The company is gearing up to launch its blood test to aid in the early detection of breast cancer in women with dense breast tissue. OncoTAb is in early stages of developing therapeutic applications, including development of Chimeric Antigen Receptor (CAR) engineered T-cells for Triple Negative Breast Cancer. The company is seeking to partner/license its technology for the development of an imaging application to detect cancer in women with dense breast tissue.

Read the full story at http://www.prweb.com/releases/2016/01/prweb13182361.htm.


'/>"/>
Source: PRWeb
Copyright©2016 Vocus, Inc.
All rights reserved


Related biology technology :

1. OncoTAb to Present Details of Blood Test for Early Detection of Breast Cancer at the 9th Annual OneMedForum
2. OncoTAb to Highlight a Tumor Specific Marker to Enable Earlier Detection of Breast Cancer in Women with Dense Breasts at 2015 SABCS
3. OncoTAb CSO Awarded the University of North Carolina’s O. Max Gardner Award
4. OncoTAb Names Dr. David L. Cooper as COO
5. CanDiag Inc. Expands Product Scope Under a New Name: OncoTab, Inc.
6. New PDI Visual Resource Highlights How Proper Disinfection Can Reduce Central Line-associated Bloodstream Infections (CLABSIs)
7. Blood Test that Monitors Dead Cancer Cell DNA Better at Tracking Spread of Melanoma
8. Biocept Launches Blood-based Test for Prostate Cancer and Expands Offering in Breast Cancer
9. NeuroQuest to Begin US Clinical Validation Trials for Alzheimers Blood Test
10. BioBridge Global, StemBioSys Announce Expanded Collaboration to Provide Human Umbilical Cord Blood Stem Cells for Research
11. NYBC Scientists Awarded Patents For Discoveries to Protect Our Blood Supply And Advance Vaccine Therapies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... the first-ever genomics analysis platform specifically designed for life science researchers to ... of pioneering researcher Rosalind Franklin, who made a major contribution to the ...
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... ComplianceOnline’s Medical ... place on 7th and 8th June 2018 in San Francisco, CA. The Summit brings ... well as several distinguished CEOs, board directors and government officials from around the world ...
(Date:10/11/2017)... ... October 11, 2017 , ... Disappearing forests and increased emissions are the ... million people each year. Especially those living in larger cities are affected by air ... one of the most pollution-affected countries globally - decided to take action. , “I ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
Breaking Biology Technology:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/3/2017)... , April 3, 2017  Data captured ... engineering platform, detected a statistically significant association ... prior to treatment and objective response of ... potential to predict whether cancer patients will ... treatment, as well as to improve both pre-infusion ...
(Date:3/30/2017)... , March 30, 2017 Trends, opportunities ... (physiological and behavioral), by technology (fingerprint, AFIS, iris recognition, ... recognition, and others), by end use industry (government and ... immigration, financial and banking, and others), and by region ... , Asia Pacific , and ...
Breaking Biology News(10 mins):